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Abstract
Levodopa continues to be the most efficacious and widely used treatment for Parkinson’s disease.
Levodopa dosing is understood to be critical for the optimal control of symptoms, and increasing the
levodopa dose is a common method to treat advancing disease. Escalating levodopa dosages coupled
with disease progression is associated with increasing likelihood of developing levodopa-induced
dyskinesia. Moreover, frequent and complicated dosing schemes, combined with limited dose
availability, leads to increasing pill burden and its associated impairment of patient adherence issues.
Levodopa/carbidopa/entacapone has been shown to improve the pharmacokinetic profile of levodopa
and provide superior symptomatic control compared with conventional levodopa/dopa decarbox-
ylase inhibitor therapy. We report four case histories describing clinical experience of using
levodopa/carbidopa/entacapone 200/50/200 mg, one of the latest doses of this formulation, in a range
of patients with Parkinson’s disease. These cases illustrate that levodopa/carbidopa/entacapone
200/50/200 mg provides improvements in symptomatic control and convenience, and that switching
to this dose was not associated with safety concerns.
Introduction
After 40 years, levodopa remains the most efficacious and
widely used treatment for Parkinson’s disease (PD), with
themajorityofpatientsrequiringlevodopatherapyatsome
point during the course of their disease [1-3]. However, as
the disease progresses it can become increasingly difficult
for patients to achieve clinical benefits, and patients will
require increasingly higher doses of levodopa. In turn, this
may lead to adherence-related issues as a result of the
increased pill burden and complex dosing schedules [4].
Failure to manage effectively the medication regimen can
contribute to functional impairment, decreased quality of
life and increased motor symptoms. Therefore, maintain-
ing patients on their therapy is a key issue for the
management of PD [5].
Conventional levodopa formulations are most commonly
administered with a dopa decarboxylase (DDC) inhibitor
(DDCI), such as benserazide (Madopar®) or carbidopa
(Sinemet®) [6,7]. In addition, controlled-release (CR)
levodopa formulations were developed in an attempt to
maintain a more stable plasma levodopa profile. In
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ON-time and poor bioavailability, compared with
immediate-release conventional levodopa [8]. In clinical
practice, some physicians may use CR-levodopa/carbi-
dopa (CR-LC; Sinemet CR®) to provide control of night-
time symptoms [9]. A third formulation of levodopa has
been developed, which provides dual-enzyme inhibition
of DDC and catechol-O-methyltransferase (COMT) [10].
This formulation of levodopa/carbidopa/entacapone
(LCE; Stalevo®) has been shown to extend the half-life of
levodopa by up to 85% and increases its bioavailability
by 35% [11,12].
Levodopa/carbidopa/entacapone has been shown to pro-
vide superior symptomatic benefits in patients with PD
compared with conventional levodopa/DDCI therapy [13].
This has been shown to translate into superior treatment
adherence, compared with the addition of separate
entacapone tablets to levodopa/DDCI [14].
LCE is available as a single tablet in a range of dose strengths,
one of the newest of which is levodopa/carbidopa/
entacapone 200/50/200 mg (Stalevo® 200; LCE 200). The
rationale for the development of the LCE 200 dose was to
increase dose flexibility and convenience by providing a
single tablet for patients requiring higher doses of levodopa
who would otherwise incur an increased pill burden; to
provide treatment for patients who have progressed on
alternative levodopa formulations and still require addi-
tional symptom control; and to potentially provide a
useful and convenient dose for night-time control and
early morning akinesia. Recently, a Phase I pharmacokinetic
study demonstrated that LCE 200 provides a superior PK
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either as a single evening dose or as a three-times daily
dosing regimen [15].
We here present case studies describing the use of LCE 200
in four patients with PD, in order to provide information
on real-world experience of when and how this new
dosing strength may be used in clinical practice.
Cases presentations
We reviewed the case histories of four patients with PD
(four males), treated at three clinics in the USA. The
patients’ ages ranged from 48 to 72 years; PD duration
ranged from 4 to 14 years (Table 1). Prior to switching to
LCE 200, the patients had received levodopa therapy for
between 2 and 12 years; all but one patient experienced
dyskinesia and/or wearing-off prior to switching (Table 1).
Further details of the individual cases are described below.
Case report 1
A 48-year-old Caucasian male with a 4-year history of PD
(Hoehn & Yahr [HY] stage 2) whose PD symptoms
consisted of asymmetric tremor at rest (left more than
right) and difficulty using the left arm. The patient had
previously received levodopa therapy for 2 years: most
recently, two LC 100/25 mg tablets five times per day, plus
entacapone 200 mg five times per day (taken with each LC
dose). Other PD medication consisted of rasagiline 1 mg/
day; the patient had also previously received ropinirole,
which caused him to feel ‘foggy minded’, and pramipex-
ole, which was associated with compulsive gambling. The
patient experienced wearing-off, characterized by a return
of tremor and restlessness, sweating and anxiety. Based on
both the physician’s and the patient’s assessment, treat-
ment was switched to one LCE 200 tablet five times per
day (levodopa 1000 mg/day), with the aim of improving
convenience and compliance. No screening diagnostic
tests were used before switching. Following the switch to
LCE 200, the patient has experienced no adverse events
(AEs) with LCE 200 and reports equal benefit compared
with his prior therapy, but with the convenience of taking
only one tablet five times daily (a total of five tablets),
instead of three tablets five times daily (a total of 15
tablets).
Case report 2
A 69-year-old Caucasian male with a 14-year history of
PD (HY OFF stage 3 / ON stage 2.5), based on clinical
diagnosis; whose PD symptoms consisted of right rest
tremor, bradykinesia (right more than left), and rigidity.
Gaitwasslow,andwhen OFFhehadimpaired balance.The
patient also has orthostatic hypotension. The patient had
previously received levodopa therapy for 12 years: most
recently, one LCE 100 tablet taken with one half-tablet of
LC 100/25 six times per day. Other PD medication
consisted of ropinirole 8 mg/day and rasagiline 1 mg/day.
The patient experienced wearing-off (with tremor, imbal-
ance, and anxiety), morning akinesia, and delayed ON. He
also had non-troublesome, peak-dose dyskinesia in the
evening. As a result of the patient’sm o r n i n ga k i n e s i a ,
delayed ON and wearing-off, the physician decided to
switch the first three doses of levodopa (LCE 100 + half-
tablet LC 100/25) to LCE 200, instead of increasing
supplemental LC 100/25. The Unified Parkinson’s Disease
Rating Scale and a comprehensive review of symptoms
assessment were used for screening before switching.
Following the switch of these doses to LCE 200, the patient
has experienced no AEs and finds the single tablet at each
dose to be more convenient. He reports less OFF time, with
reduced risk of falls. His medication has a quicker onset of
action in the morning. Mild evening dyskinesia persisted,
but stopping the additional half-tablet dose of LC in the
evening led to less dyskinesia. Subsequently, the ropinirole
was switched to once-daily prolonged-release formulation,
once-daily rasagiline continued, and the additional LC
100/25 with later LCE 100 doses was replaced with LCE
150. He found this medication regimen with fewer daily
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dyskinesia or other side effects.
Case report 3
A 72-year-old Caucasian male with an 8-year history of PD
(HY stage 2) whose PD symptoms consisted of mild right
and slight left rest tremor, mildly decreased co-ordination
on the right, slightly decreased coordination on the left,
mildly increased tone on the right, and slightly increased
tone on the left. The patient previously received levodopa
therapy for 5 years: one LC 100/25 mg tablet five times per
day, switched to one LCE 150 tablet four times per day and
CR-LC 200/50 mg administered at bedtime. Over the
course of his disease, PD medication consisted of selegiline,
pergolide mesylate, amantadine and rasagiline. All were
stopped due to side effects or lack of efficacy. His current
medications included LCE 150 mg, four times per day and
ropinirole 3 mg, three times per day. The patient experi-
enced no motor complications on his current therapy. The
patient noted no clear OFF time, but felt that his ON time
wasnotasgoodasithadbeen.Healsonoticedanincreased
difficulty in performing activities of daily living (ADL)
throughouttheday,andthephysicianfoundaworseningof
symptoms upon examination. As a result of these patient
and physician assessments, treatment was switched to one
LCE 200 tablet four times per day. No screening diagnostic
tests were used before switching. Following the switch to
LCE 200, the patient has experienced no AEs. He reports
that his physical functioning has improved, in terms of
walking, ADL and personal care. Although he noticed no
change in function during the night, he notes that he is
turning ON much quicker in the morning. He reports that
he turns ON in about 30 minutes now where it used to take
60–90 minutes.
Case report 4
A 65-year-old Caucasian male with a 13-year history of PD
(HY stage 2.5), based on physical examination and
symptoms, whose PD symptoms consisted of rest tremor
on the left, moderately decreased coordination on the left,
mildly decreased coordination on the right, mildly
increased tone on the left and slightly increased tone on
the right. The patient previously received levodopa therapy
for 8 years: one LC 100/25 mg tablet three times per day,
increasedtofivetimesperday;switchedtooneLCE100 mg
tablet six times per day, eventually increased to one LCE
150 mg tablet six times per day. Other PD medication
consisted of selegiline, ropinirole, entacapone and rasagi-
line. The patient experienced dyskinesia for approximately
5% of the day, and wearing-off for approximately 25% of
the day. He also experienced occasional dose failure. The
patient experienced significant OFF time after his 07:00 and
14:00 dose, almost every day, and physical examination
elicited some dyskinesias. For these reasons, the patient’s
treatment was switched to LCE (a total of 1000 mg
levodopa/day), administered as a combination of LCE
150 and LCE 200, divided into six doses as follows: LCE
200 at 07:00 and 14:00, LCE 150 at 05:00, 12:00, 17:00,
and 21:00. The physician’s rationale for this treatment
regimen was that, by only increasing the doses given at
07:00 and 14:00 (when the patient reported experiencing
significant OFF time), the patient’s OFF time might
improve, without increasing his dyskinesia. No screening
diagnostic tests were used before switching. The patient
reports a significant improvement in ON time, with no
worsening of dyskinesias.
Discussion
In this case series, all four patients experienced important
benefits as a result of switching to LCE 200 mg treatment
from their previous levodopa therapy: the three patients
(Cases 2–4) who had progressed on high levodopa/LCE
doses, experienced benefits in terms of symptom control,
with two patients reporting improvements in ON time/
reduction in OFF time (Cases 2 and 4), and one patient
reporting improvements in physical functioning and
quality of life, as determined by ADL (Case 3). For one
patient (Case 2), a decrease in the OFF time may have
reduced the risk of falls, and switching to doses of LCE
200 considerably simplified the patient’s dosing schedule.
Interestingly, a levodopa dose reduction in the evening
was useful for managing dyskinesia in this patient. The
youngest patient (Case 1), who had the shortest duration
of PD and previous levodopa therapy, experienced equal
Table 1. Summary of case reports of four patients with Parkinson’s disease switched to LCE 200
Case 1 Case 2 Case 3 Case 4
Sex Male Male Male Male
Age (years) 48 69 72 65
Duration of Parkinson’s disease (years) 4 14 8 13
Hoehn & Yahr stage 2 OFF 3/ON 2.5 2 2.5
Duration of levodopa therapy (years) 2 12 5 8
Motor complications Wearing-off Dyskinesia, wearing-off, delayed
ON time, morning akinesia
None Dyskinesia, wearing-off
Symptom benefit? Equal Yes Yes Yes
Convenience benefit? Yes Yes Not stated Not stated
AEs associated with switching to LCE 200? No No No No
AEs, adverse events; LCE 200, levodopa/carbidopa/entacapone 200/50/200 mg.
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but reported that LCE 200 was more convenient than
his previous treatment, since it involved taking one tablet
five times per day, rather than three tablets five times per
day. Dosing convenience and improved symptom control
were the most common reason for switching to the LCE
200 dose.
All patients in this report received two to six doses of
LCE 200 per day and all patients except for one (Case 3)
were experiencing motor complications prior to the
switch to LCE 200. Use of LCE 200 was associated with
an improvement in motor complications in all three
patients. Wearing-off symptoms, including the non-motor
symptoms, such as anxiety and swearing, improved in
all three patients. Dyskinesias were not increased in the
two patients who experienced dyskinesia before the
switch to LCE 200 (Cases 2 and 4). Importantly, none of
the patients reported any AEs as a result of switching to
LCE 200.
Switching was performed either directly from LC 100 plus
entacapone (Case 1), or from LCE 150 (Cases 2–4); only
one patient (Case 2) underwent diagnostic screening tests
prior to switching.
LCE 200 was shown to be effective for additional control
of morning akinesia (Case 2), and during the night in a
patient previously treated with CR-LC 200/50 mg at
bedtime in addition to LCE 150 (Case 3).
Conclusions
ThesecasesillustratethatLCE200isausefulnewdose,with
thepotentialtoprovideimprovedsymptomcontrol,greater
dosing flexibility and convenience, and additional control
overnight and for morning akinesia. In these cases, switch-
ing to LCE 200 was not associated with safety concerns,
including increases in dyskinesia, which may be seen with
increasing doses of conventional levodopa. The number of
case reports presented herein is limited, since the 200 mg
dose has only recently been included in clinical practice.
FurtherclinicalexperiencewithLCE200willproveusefulin
expanding our knowledge of the potential benefits of this
new dose. However, given that levodopa dosing is a key
issue for the symptomatic treatment of PD, the availability
of additional levodopa doses will allow physicians greater
prescribing flexibility, which may enable a more individua-
lized approach to treating patients with PD.
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